Langbahn Team – Weltmeisterschaft

Methylenedioxybenzylamphetamine

Methylenedioxybenzyl­amphetamine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C17H19NO2/c1-13(18-11-14-5-3-2-4-6-14)9-15-7-8-16-17(10-15)20-12-19-16/h2-8,10,13,18H,9,11-12H2,1H3
    Key: DWLUHTUYTBWOLO-UHFFFAOYSA-N
  • C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
Properties
C17H19NO2
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a psychedelic drug. It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[1]

Legality

United Kingdom

MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)". Parliamentary Debates (Hansard). 23 July 1996.
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.


Quelle: https://en.wikipedia.org/wiki/3,4-methylenedioxy-N-benzylamphetamine